EPCOR FL1 Phase 3 Data: Insights from ASH 2025 on Follicular Lymphoma

23 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join Dr. Urshila Durani, a lymphoma physician at Mayo Clinic, as she interviews Dr. Joshua Brody from Mount Sinai at the Oncology Brothers Advancements in Oncology event during ASH 2025. In this interview, they dive deep into the groundbreaking EPCOR FL1 phase 3 study, which compares EPCOR squared versus R-squared in relapsed or refractory follicular lymphoma.
Dr. Brody shares his insights on the efficacy and safety profiles of these treatments, discussing the implications for community oncologists and the evolving landscape of follicular lymphoma therapy. They also explore the concept of "incurable" diseases and the potential for future cures, as well as strategies for managing increased infection risks associated with new therapies.
Tune in for an engaging conversation filled with expert opinions, clinical insights, and a hopeful outlook on the future of follicular lymphoma treatment.
Topics Covered:
• EPCOR FL1 phase 3 study results
• Efficacy and safety of EPCOR squared vs. R-squared
• Managing infection risks in patients
• The evolving definition of "incurable" diseases

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research!

Website: https://oncupdates.com/
Mail: [email protected]
X/twitter: https://x.com/OncUpdates

#ASH2025 #FollicularLymphoma #EPCOREFL1 #BispecificAntibody #Lymphoma #OncologyBrothers #Hematology
Categoria
Oncology
Commenta per primo questo video.

Prossimo